title: Effects of continuous positive airway pressure on blood pressure and daytime sleepiness in obstructive sleep apnea patients with coronary heart diseases under optimal medications.
abstract: BACKGROUND
  Continuous positive airway pressure (CPAP) is an effective therapy for obstructive sleep apnea (OSA). However, for patients who already have OSA and coronary heart diseases (CHD) with optimal medications, whether CPAP can reduce the blood pressure (BP) is not clear. This is a controlled study to evaluate the effects of CPAP on BP in Chinese cohorts with CHD under optimal medications.
  
  
  METHODS
  Twenty-four patients with CHD and moderate to severe OSA were treated with CPAP and standard care for 1 month. Twenty-four matched control patients were only treated with standard care alone. Baseline demographic data as well as sleep study data was recorded in all patients. Office blood pressure, heart rate, Epworth sleepiness scale (ESS) score, and quality of life (SF-36) of the two groups were compared after 1-month treatment.
  
  
  RESULTS
  Compared with control group, CPAP treatment markedly reduced the morning diastolic BP (Δ -0.8 ± 6.0 vs. Δ -5.1 ± 6.5, respectively, P = 0.023) and improved ESS scores (Δ -0.5 ± 3.2 vs. Δ -5.2 ± 3.1, P < 0.001). In contrast, there were no significant changes in systolic BP (Δ -0.3 ± 7.3 vs. Δ -3.8 ± 11.8, P = 0.225), heart rate, and quality of life.
  
  
  CONCLUSIONS
  CPAP treatment for 1 month was associated with significant reduction in diastolic BP and improvement in ESS score. For patients with moderate to severe OSA and CHD under optimal medications, CPAP treatment leads to effective reduction in diastolic blood pressure and improvement in daytime sleepiness.
authors.affiliation: Center for Pulmonary Vascular Disease Diagnosis and Treatment, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Road, Xicheng District, Beijing, 100037, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhao
authors.forename: Zhi-Hong
authors.initials: ZH
authors.lastname: Liu
authors.forename: Qin
authors.initials: Q
authors.lastname: Luo
authors.forename: Zhi-Hui
authors.initials: ZH
authors.lastname: Zhao
authors.forename: Hong-Liang
authors.initials: HL
authors.lastname: Zhang
authors.forename: Yong
authors.initials: Y
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D015897:Comorbidity; D045422:Continuous Positive Airway Pressure; D003327:Coronary Disease / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D006970:Disorders of Excessive Somnolence / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D011788:Quality of Life; D020181:Sleep Apnea, Obstructive / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*
chemical_list: D000959:Antihypertensive Agents; D002316:Cardiotonic Agents